FLNB (Filamin-B) variants and mutations
FLNB (also known as Filamin-B) is a human protein-coding gene encoding a filamin-B protein. It crosslinks actin and organizes cytoskeletal signaling in cartilage, bone, and other tissues during development. Pathogenic variants cause a broad skeletal-dysplasia spectrum including atelosteogenesis, Larsen syndrome, and spondylocarpotarsal syndrome. This analysis covers 3,569 FLNB variants and mutations. Of these, 70% have computational variant effect predictions. Disease context includes Larsen syndrome, atelosteogenesis type I, and spondylocarpotarsal synostosis syndrome. Example FLNB variants include P2S, P2T, and P2L.
Variant analysis overview
- Gene: FLNB
- Protein: Filamin-B
- UniProt accession: O75369
- Organism: Homo sapiens
- Variants analyzed: 3569
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 3,344 unspecified-consequence records; 105 missense variants; 97 synonymous variants; 7 stop-gained variants; 10 frameshift variants; 2 in-frame deletions; 1 in-frame insertions; 3 splice-region variants
- Prediction scores: 2,487 variants have prediction scores (70% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Larsen syndrome, atelosteogenesis type I, spondylocarpotarsal synostosis syndrome, atelosteogenesis type III, Boomerang dysplasia, Autosomal dominant Larsen syndrome, Spondylocarpotarsal synostosis, Joubert syndrome and related disorders, open-angle glaucoma, hereditary disease, filamin-related bone disorder, glaucoma.
Protein structure and variant hotspots
- Protein features: 2 domains; 26 post-translational modification sites.
- Structural context: 410 variants have structural context.
- PTM context: 36 variants overlap post-translational modification sites.
- Experimental data: 90 protein positions have experimental scores. Source: FLNB Filamin/ABP280 repeat-like domain domainome 1.0.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable FLNB variants
Examples include P2S, P2T, P2L, P2P, V3I, V3L, V3V, T4R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- P2S (p.Pro2Ser), ExAC rs758201060, TOPMed rs758201060, gnomAD rs758201060, REVEL 0.66, CADD 24.40
- P2T (p.Pro2Thr), gnomAD 3-58008568-C-A, REVEL 0.67, CADD 26.50
- P2L (p.Pro2Leu), gnomAD 3-58008569-C-T, REVEL 0.67, CADD 29.60
- P2P (p.Pro2Pro), gnomAD 3-58008570-G-T, CADD 14.60
- V3I (p.Val3Ile), gnomAD 3-58008571-G-A, REVEL 0.29, CADD 24.40
- V3L (p.Val3Leu), gnomAD 3-58008571-G-T, REVEL 0.27, CADD 24.70
- V3V (p.Val3Val), rs199846967, gnomAD 3-58008573-A-G, CADD 11.80
- T4R (p.Thr4Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- T4T (p.Thr4Thr), gnomAD 3-58008576-C-A, CADD 10.20
- T4S (p.Thr4Ser), gnomAD 3-58078501-A-T, CADD 1.69
- E5G (p.Glu5Gly), Ensembl rs1576576258, REVEL 0.83, CADD 32.00
- E5K (p.Glu5Lys), NCI-TCGA TCGA novel, REVEL 0.76, CADD 26.60, Variant assessed as somatic; moderate impact.
- E5Q (p.Glu5Gln), gnomAD rs1420322834, REVEL 0.69, CADD 30.00
- E5* (p.Glu5Ter), gnomAD 3-58008577-G-T, CADD 41.00
- E5E (p.Glu5Glu), rs757329160, gnomAD 3-58008579-G-A, CADD 13.80
- D7V (p.Asp7Val), ExAC rs781272365, gnomAD rs781272365, REVEL 0.91, CADD 31.00
- D7E (p.Asp7Glu), gnomAD 3-58008585-T-G, REVEL 0.67, CADD 22.60
- L8I (p.Leu8Ile), ESP rs376917060, ExAC rs376917060, gnomAD rs376917060, REVEL 0.74, CADD 24.90
- L8P (p.Leu8Pro), gnomAD rs1166656084
- L8V (p.Leu8Val), gnomAD 3-58008586-C-G, REVEL 0.80, CADD 23.20
- L8L (p.Leu8Leu), rs376917060, gnomAD 3-58008586-C-T, CADD 14.30
- A9P (p.Ala9Pro), cosmic curated COSV55869
- A9D (p.Ala9Asp), gnomAD 3-58008590-C-A, REVEL 0.84, CADD 24.90
- A9A (p.Ala9Ala), rs749670256, gnomAD 3-58008591-T-A, CADD 16.20
- E10* (p.Glu10Ter), cosmic curated COSV10880
- E10A (p.Glu10Ala), TOPMed rs888581942, gnomAD rs888581942, REVEL 0.69, CADD 25.50
- E10K (p.Glu10Lys), ExAC rs769055809, TOPMed rs769055809, gnomAD rs769055809, REVEL 0.77, CADD 27.10
- E10E (p.Glu10Glu), gnomAD 3-58008594-G-A, CADD 14.40
- D11E (p.Asp11Glu), TOPMed rs2097093756, REVEL 0.74, CADD 26.20
- D11N (p.Asp11Asn), ExAC rs772777005, TOPMed rs772777005, gnomAD rs772777005, REVEL 0.83, CADD 32.00
- D11G (p.Asp11Gly), gnomAD 3-58008596-A-G, REVEL 0.96, CADD 32.00
- D11D (p.Asp11Asp), gnomAD 3-58008597-C-T, CADD 15.10
- A12S (p.Ala12Ser), gnomAD 3-58008598-G-T, REVEL 0.77, CADD 31.00
- P13T (p.Pro13Thr), gnomAD 3-58008601-C-A, REVEL 0.81, CADD 24.40
- W14* (p.Trp14Ter), TOPMed rs2097093758, gnomAD rs2097093758, CADD 41.00
- W14R (p.Trp14Arg), NCI-TCGA Cosmic COSV5588, cosmic curated COSV55884, Variant assessed as somatic; moderate impact.
- W14S (p.Trp14Ser), cosmic curated COSV55896
- K15E (p.Lys15Glu), gnomAD 3-58008607-A-G, REVEL 0.88, CADD 32.00
- K15R (p.Lys15Arg), gnomAD 3-58008608-A-G, REVEL 0.87, CADD 25.70
- K16E (p.Lys16Glu), gnomAD 3-58008610-A-G, REVEL 0.67, CADD 25.50
- K16N (p.Lys16Asn), gnomAD 3-58008612-G-C, REVEL 0.56, CADD 26.60
- I17I (p.Ile17Ile), rs2097093763, gnomAD 3-58008615-C-T, CADD 12.70
- Q18P (p.Gln18Pro), gnomAD rs1244879124, REVEL 0.94, CADD 25.80
- Q18Q (p.Gln18Gln), rs1460396041, gnomAD 3-58008618-G-A, CADD 13.60
- Q19* (p.Gln19Ter), gnomAD 3-58008619-C-T, CADD 38.00
- N20K (p.Asn20Lys), gnomAD 3-58008624-C-A, REVEL 0.60, CADD 24.40
- T21A (p.Thr21Ala), TOPMed rs2097093776
- T21R (p.Thr21Arg), rs2477192945, ClinGen CA353412903, ClinVar RCV003723791, Uncertain significance, not provided
- T21T (p.Thr21Thr), rs539469179, gnomAD 3-58008627-G-T, CADD 7.97
- F22S (p.Phe22Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- T23A (p.Thr23Ala), Ensembl rs2097093789
- T23I (p.Thr23Ile), gnomAD 3-58008632-C-T, REVEL 0.95, CADD 28.30
- R24C (p.Arg24Cys), gnomAD 3-58008634-C-T, REVEL 0.90, CADD 32.00
- R24G (p.Arg24Gly), gnomAD 3-58008634-C-G, REVEL 0.92, CADD 29.70
- R24R (p.Arg24Arg), gnomAD 3-58008636-C-G, CADD 14.60
- R24W (p.Arg24Trp), rs1195118329, gnomAD 3-58078504-C-T, CADD 1.06
- R9del (p.Arg9del), rs2097204668, gnomAD 3-58078504-CGGA-C, CADD 0.70
- R24Q (p.Arg24Gln), rs544099876, gnomAD 3-58078505-G-A, CADD 0.93
- R24K (p.Arg24Lys), gnomAD 3-58078508-G-A, CADD 5.89
- C26S (p.Cys26Ser), gnomAD 3-58008640-T-A, REVEL 0.89, CADD 29.20
- C26W (p.Cys26Trp), gnomAD 3-58008642-C-G, REVEL 0.84, CADD 31.00
- N27S (p.Asn27Ser), rs760976111, NCI-TCGA Cosmic COSV9991, cosmic curated COSV99914, Ensembl rs760976111, REVEL 0.93, CADD 29.20, Variant assessed as somatic; moderate impact.
- N27H (p.Asn27His), gnomAD 3-58008643-A-C, REVEL 0.94, CADD 31.00
- N27N (p.Asn27Asn), rs770671756, gnomAD 3-58008645-C-T, CADD 13.00
- E28V (p.Glu28Val), rs1428809108, ClinGen CA353412955, ClinVar RCV003144015, TOPMed rs1428809108, REVEL 0.95, CADD 32.00, Uncertain significance, not provided
- E28* (p.Glu28Ter), gnomAD 3-58008646-G-T, CADD 40.00
- E28K (p.Glu28Lys), gnomAD 3-58008646-G-A, REVEL 0.91, CADD 32.00
- E28E (p.Glu28Glu), rs1197563298, gnomAD 3-58008648-G-A, CADD 14.60
- H29Y (p.His29Tyr), gnomAD rs1235295927, REVEL 0.84, CADD 28.30
- H29R (p.His29Arg), rs1447330963, gnomAD 3-58078496-A-G, CADD 6.31
- H29P (p.His29Pro), rs1447330963, gnomAD 3-58078496-A-C, CADD 6.12
- H29H (p.His29His), gnomAD 3-58078497-T-C, CADD 2.28
- L30V (p.Leu30Val), ExAC rs776287368, gnomAD rs776287368, REVEL 0.91, CADD 26.70
- K31M (p.Lys31Met), ExAC rs759061129, gnomAD rs759061129, REVEL 0.82, CADD 32.00
- K31R (p.Lys31Arg), ExAC rs759061129, gnomAD rs759061129, REVEL 0.43, CADD 23.80
- K31T (p.Lys31Thr), gnomAD 3-58008656-A-C, REVEL 0.79, CADD 25.60
- C32S (p.Cys32Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- C32C (p.Cys32Cys), rs765325091, gnomAD 3-58008660-C-T, CADD 15.50
- V33V (p.Val33Val), gnomAD 3-58008663-G-C, CADD 14.00
- N34S (p.Asn34Ser), rs1481548213, ClinGen CA353412996, ClinVar RCV003844112, TOPMed rs1481548213, REVEL 0.58, CADD 23.20, Uncertain significance, not provided
- N34K (p.Asn34Lys), gnomAD 3-58008666-C-G, REVEL 0.69, CADD 25.00
- R36C (p.Arg36Cys), cosmic curated COSV99911, REVEL 0.83, CADD 32.00
- R36H (p.Arg36His), rs142568031, ClinGen CA2467454, cosmic curated COSV10609, ClinVar RCV000508479, REVEL 0.62, CADD 33.00, Conflicting interpretations, Connective tissue disorder; not provided; not specified
- R36L (p.Arg36Leu), rs142568031, ClinGen CA2467455, ClinVar RCV001888799, ClinVar RCV002552923, REVEL 0.91, CADD 32.00, Uncertain significance, Inborn genetic diseases; not provided
- I37T (p.Ile37Thr), cosmic curated COSV55875
- I37V (p.Ile37Val), rs1249133663, NCI-TCGA Cosmic COSV5587, cosmic curated COSV55879, gnomAD rs1249133663, REVEL 0.41, CADD 22.50, Variant assessed as somatic; moderate impact.
- I37I (p.Ile37Ile), rs2097093845, gnomAD 3-58008675-C-T, CADD 14.20
- G38D (p.Gly38Asp), TOPMed rs2097093849
- G38S (p.Gly38Ser), gnomAD 3-58008676-G-A, REVEL 0.43, CADD 23.10
- N39S (p.Asn39Ser), gnomAD 3-58008680-A-G, REVEL 0.50, CADD 24.60
- N39N (p.Asn39Asn), gnomAD 3-58008681-C-T, CADD 14.40
- L40V (p.Leu40Val), ExAC rs751263946, TOPMed rs751263946, gnomAD rs751263946, REVEL 0.92, CADD 26.10, Likely benign
- L40L (p.Leu40Leu), rs751263946, gnomAD 3-58008682-C-T, CADD 14.90
- L40Q (p.Leu40Gln), gnomAD 3-58008683-T-A, REVEL 0.99, CADD 32.00
- Q41* (p.Gln41Ter), cosmic curated COSV10962
- Q41Q (p.Gln41Gln), rs143729485, gnomAD 3-58008687-G-A, CADD 13.70
- T42A (p.Thr42Ala), rs1198656971, ClinGen CA353413046, ClinVar RCV002815713, TOPMed rs1198656971, REVEL 0.45, CADD 22.50, Uncertain significance, not provided
- T42N (p.Thr42Asn), Ensembl rs965535331, Uncertain significance, Inborn genetic diseases
- D43N (p.Asp43Asn), rs781324487, NCI-TCGA Cosmic COSV5588, cosmic curated COSV55888, ExAC rs781324487, REVEL 0.91, CADD 32.00, Variant assessed as somatic; moderate impact.
- D43Y (p.Asp43Tyr), gnomAD 3-58008691-G-T, REVEL 0.97, CADD 32.00
- D43D (p.Asp43Asp), rs750512800, gnomAD 3-58008693-C-T, CADD 14.80
- L44L (p.Leu44Leu), gnomAD 3-58008696-G-C, CADD 14.30
- S45N (p.Ser45Asn), Ensembl rs2097093883, REVEL 0.62, CADD 28.50
- S45G (p.Ser45Gly), gnomAD 3-58008697-A-G, REVEL 0.39, CADD 23.10
- S45S (p.Ser45Ser), gnomAD 3-58008699-C-T, CADD 15.90
- S45C (p.Ser45Cys), gnomAD 3-58078498-A-T, CADD 1.01
- D46N (p.Asp46Asn), cosmic curated COSV10641, TOPMed rs1171618218, gnomAD rs1171618218, REVEL 0.92, CADD 32.00
- D46R (p.Asp46Arg), gnomAD 3-58008698-G-GC, CADD 33.00
- D46D (p.Asp46Asp), gnomAD 3-58008702-C-T, CADD 13.20
- G47R (p.Gly47Arg), cosmic curated COSV10460, Ensembl rs977421756
- G47E (p.Gly47Glu), gnomAD 3-58008704-G-A, REVEL 0.98, CADD 32.00
- R49L (p.Arg49Leu), rs1322262022, ClinGen CA353413093, ClinVar RCV004389455, TOPMed rs1322262022, REVEL 0.91, CADD 32.00, Uncertain significance, Inborn genetic diseases
- R49W (p.Arg49Trp), Ensembl rs2097093895, REVEL 0.85, CADD 24.60
- R49R (p.Arg49Arg), rs756170382, gnomAD 3-58008711-G-A, CADD 15.80
- I51L (p.Ile51Leu), TOPMed rs1260817076, gnomAD rs1260817076, REVEL 0.84, CADD 31.00, Uncertain significance, not provided
- I51V (p.Ile51Val), rs1260817076, ClinGen CA353413101, ClinVar RCV003827318, TOPMed rs1260817076, REVEL 0.73, CADD 27.90, Uncertain significance, not provided
- I51I (p.Ile51Ile), gnomAD 3-58008717-C-T, CADD 13.40
- A52V (p.Ala52Val), gnomAD 3-58008719-C-T, REVEL 0.83, CADD 27.90
- A52A (p.Ala52Ala), rs1331391516, gnomAD 3-58008720-G-T, CADD 14.70
- L53L (p.Leu53Leu), gnomAD 3-58008723-G-C, CADD 13.90
- L54S (p.Leu54Ser), gnomAD 3-58008722-TG-T, CADD 27.90
- L54L (p.Leu54Leu), rs780601404, gnomAD 3-58008726-C-T, CADD 8.99
- E55K (p.Glu55Lys), cosmic curated COSV55901
- E55Q (p.Glu55Gln), rs768998920, NCI-TCGA Cosmic COSV5590, NCI-TCGA Cosmic COSV9991, cosmic curated COSV99913, REVEL 0.93, CADD 32.00, Variant assessed as somatic; moderate impact.
- p.Glu55 Leu57del, rs2097093907, gnomAD 3-58008721-CTGCTC, CADD 22.80
- L57P (p.Leu57Pro), TOPMed rs1306005428, gnomAD rs1306005428, REVEL 0.99, CADD 33.00
- S58I (p.Ser58Ile), rs779370264, ClinGen CA2467464, ClinVar RCV004389456, ExAC rs779370264, REVEL 0.93, CADD 32.00, Uncertain significance, Inborn genetic diseases
- S58N (p.Ser58Asn), ExAC rs779370264, gnomAD rs779370264, REVEL 0.81, CADD 29.40, Uncertain significance
- S58R (p.Ser58Arg), TOPMed rs2097093923, gnomAD rs2097093923, REVEL 0.87, CADD 26.60
- S58S (p.Ser58Ser), rs2097093923, gnomAD 3-58008738-C-T, CADD 15.80
- Q59* (p.Gln59Ter), ExAC rs748397777, gnomAD rs748397777, CADD 39.00, Uncertain significance
- K60E (p.Lys60Glu), gnomAD rs1291636394, REVEL 0.86, CADD 32.00
- R61C (p.Arg61Cys), gnomAD rs1241394741, Uncertain significance
- R61G (p.Arg61Gly), rs1241394741, ClinGen CA353413166, ClinVar RCV002623718, gnomAD rs1241394741, REVEL 0.51, CADD 25.50, Uncertain significance, not provided
- R61H (p.Arg61His), ExAC rs770724869, gnomAD rs770724869, REVEL 0.26, CADD 16.10
- R61L (p.Arg61Leu), ExAC rs770724869, gnomAD rs770724869, REVEL 0.29, CADD 19.80, Uncertain significance, not provided
- R61S (p.Arg61Ser), gnomAD 3-58008745-C-A, REVEL 0.38, CADD 24.80
- R61P (p.Arg61Pro), gnomAD 3-58008746-G-C, REVEL 0.36, CADD 23.00
- R61R (p.Arg61Arg), rs918873893, gnomAD 3-58008747-C-T, CADD 15.00
- M62L (p.Met62Leu), 1000Genomes rs566615110, ExAC rs566615110, TOPMed rs566615110, gnomAD rs566615110, REVEL 0.70, CADD 24.90, Uncertain significance
- M62V (p.Met62Val), rs566615110, ClinGen CA353413171, ClinVar RCV003688236, 1000Genomes rs566615110, REVEL 0.78, CADD 24.50, Uncertain significance, not provided
- M62R (p.Met62Arg), gnomAD 3-58008749-T-G, REVEL 0.97, CADD 32.00
- M62I (p.Met62Ile), gnomAD 3-58008750-G-A, REVEL 0.77, CADD 29.90
- Y63H (p.Tyr63His), rs1378933541, ClinGen CA353413179, ClinVar RCV001145589, ClinVar RCV002298874, REVEL 0.55, CADD 23.40, Uncertain significance, not provided; FLNB-Related Spectrum Disorders
- Y63Y (p.Tyr63Tyr), gnomAD 3-58008753-C-T, CADD 14.10
- R64H (p.Arg64His), ExAC rs759185725, gnomAD rs759185725
- R64L (p.Arg64Leu), ExAC rs759185725, gnomAD rs759185725, REVEL 0.87, CADD 26.10
- R64P (p.Arg64Pro), ExAC rs759185725, gnomAD rs759185725, REVEL 0.82, CADD 26.50
- R64C (p.Arg64Cys), gnomAD 3-58008754-C-T, REVEL 0.78, CADD 32.00
- R64R (p.Arg64Arg), gnomAD 3-58008756-C-G, CADD 16.10
- K65N (p.Lys65Asn), Ensembl rs2106655440, REVEL 0.84, CADD 31.00, Uncertain significance
- K65R (p.Lys65Arg), ExAC rs775339823, TOPMed rs775339823, gnomAD rs775339823, REVEL 0.73, CADD 26.30
- K65T (p.Lys65Thr), ExAC rs775339823, TOPMed rs775339823, gnomAD rs775339823, REVEL 0.93, CADD 32.00
- K65K (p.Lys65Lys), rs2106655440, gnomAD 3-58008759-G-A, CADD 15.10
- Y66C (p.Tyr66Cys), ExAC rs763897198, gnomAD rs763897198, REVEL 0.93, CADD 32.00
- Y66N (p.Tyr66Asn), cosmic curated COSV99915
- H67N (p.His67Asn), ExAC rs751371914, gnomAD rs751371914, REVEL 0.48, CADD 22.80, Uncertain significance
- H67Y (p.His67Tyr), rs751371914, ClinGen CA2467473, ClinVar RCV000714843, ClinVar RCV000714844, REVEL 0.69, CADD 26.80, Uncertain significance, Larsen syndrome; Boomerang dysplasia
- Q68* (p.Gln68Ter), cosmic curated COSV55900
- Q68E (p.Gln68Glu), cosmic curated COSV55874
- R69L (p.Arg69Leu), NCI-TCGA Cosmic COSV9991, cosmic curated COSV99913, Variant assessed as somatic; moderate impact.
- R69W (p.Arg69Trp), rs369273712, ClinGen CA2467475, ClinVar RCV001965520, ClinVar RCV005834145, REVEL 0.86, CADD 31.00, Uncertain significance, not provided; Inborn genetic diseases
- R69P (p.Arg69Pro), gnomAD 3-58008770-G-C, REVEL 0.93, CADD 32.00
- P70P (p.Pro70Pro), gnomAD 3-58008774-C-T, CADD 16.10
- T71S (p.Thr71Ser), rs1254928825, ClinGen CA353413231, ClinVar RCV001878094, ClinVar RCV004538585, REVEL 0.33, CADD 23.50, Uncertain significance, FLNB-related disorder; not provided
- T71T (p.Thr71Thr), rs1485110875, gnomAD 3-58008777-C-T, CADD 14.90
- R73L (p.Arg73Leu), NCI-TCGA Cosmic COSV5587, cosmic curated COSV55879, Variant assessed as somatic; moderate impact.
- R73P (p.Arg73Pro), gnomAD 3-58008782-G-C, REVEL 0.93, CADD 33.00
- Q74* (p.Gln74Ter), gnomAD rs1186772418, CADD 40.00
- Q74S (p.Gln74Ser), gnomAD 3-58008781-CGCCAG, CADD 33.00
- M75T (p.Met75Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- M75L (p.Met75Leu), gnomAD 3-58008787-A-T, REVEL 0.76, CADD 25.00
- Q76H (p.Gln76His), rs2477194997, ClinGen CA353413271, ClinVar RCV003685673, REVEL 0.72, CADD 28.60, Uncertain significance, not provided
- L77L (p.Leu77Leu), rs750637469, gnomAD 3-58008795-C-T, CADD 9.05
- E78G (p.Glu78Gly), rs756221503, ClinGen CA2467477, ClinVar RCV000325786, ClinVar RCV002520164, REVEL 0.97, CADD 32.00, Uncertain significance, not provided; FLNB-Related Spectrum Disorders
- N79S (p.Asn79Ser), cosmic curated COSV10809
- N79N (p.Asn79Asn), rs2097093987, gnomAD 3-58008801-T-C, CADD 11.80
- V80M (p.Val80Met), gnomAD rs1170343161, REVEL 0.88, CADD 32.00
- S81S (p.Ser81Ser), gnomAD 3-58008807-C-A, CADD 10.60
- V82M (p.Val82Met), TOPMed rs2097093997
Public FLNB analysis runs
- FLNB analysis run — FLNB (3,569 variants) — completed 2026-08-20